Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH

This study has been completed.
Sponsor:
Information provided by:
Vecta Ltd.
ClinicalTrials.gov Identifier:
NCT00818870
First received: January 6, 2009
Last updated: January 26, 2010
Last verified: January 2010

January 6, 2009
January 26, 2010
December 2008
June 2009   (final data collection date for primary outcome measure)
To assess whether Vecam 40/300 administered at bedtime w/o food is pharmacodynamically superior to Omeprazole 20 mg administered before breakfast, calculated as percent time gastric pH ≥4 for the 24-hour interval after the fifth dose. [ Time Frame: 5 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00818870 on ClinicalTrials.gov Archive Site
  • To assess whether Vecam 40/300 administered at bedtime w/o food is pharmacodynamically superior to Vecam 20/300 administered at bedtime w/o food calculated as percent time gastric pH ≥4 for the 24-hour interval after the fifth dose. [ Time Frame: 5 days ] [ Designated as safety issue: No ]
  • To assess whether Vecam 20/300 administered at bedtime w/o food is pharmacodynamically superior to Omeprazole 20 mg administered before breakfast, calculated as percent time gastric pH ≥4 for the 24-hour interval after the fifth dose. [ Time Frame: 5 days ] [ Designated as safety issue: No ]
  • To assess whether Vecam 40/300 administered at bedtime w/o food is pharmacodynamically superior to Vecam 20/300 administered at bedtime w/o food calculated as percent time gastric pH ≥4 during nocturnal hours after the fifth dose. [ Time Frame: 5 days ] [ Designated as safety issue: No ]
  • To assess whether Vecam 40/300 administered at bedtime w/o food is pharmacodynamically superior to Omeprazole 20 mg administered before breakfast calculated as percent time gastric pH ≥4 during nocturnal hours after the fifth dose [ Time Frame: 5 days ] [ Designated as safety issue: No ]
  • To assess whether Vecam 20/300 administered at bedtime w/o food is pharmacodynamically superior to Omeprazole 20 mg administered before breakfast calculated as percent time gastric pH ≥4 during nocturnal hours after the fifth dose. [ Time Frame: 5 days ] [ Designated as safety issue: No ]
  • To asses Vecam 40/300 administered at bedtime w/o food vs. Omeprazole 20 mg administered before breakfast calculated as percent time pH ≥4 during 24-hour interval and nocturnal hours at early dosing days. [ Time Frame: 5 days ] [ Designated as safety issue: No ]
  • To assess the safety of Vecam 40/300 and Vecam 20/300 administered at bedtime vs. Omeprazole 20 mg administered before breakfast during treatment period. [ Time Frame: 5 days ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH
A Randomized, Open-Label, Cross-Over, Dose-Ranging Study to Assess the Effect of Vecam 40/300 and Vecam 20/300 Administered at Bedtime Compared to Omeprazole 20 mg Administered Before Breakfast on Gastric pH

The study is designed to assess and compare the effect of Vecam 40/300, Vecam 20/300 and Omeprazole 20 mg (a standard FDA approved GERD treatment) on the control of gastric pH.

Eligible H. pylori negative, normal gastric acid secreting, healthy volunteers will be treated by the study medications in a randomized, open-label, cross-over study.Up to 60 volunteers may be enrolled to ensure that at least 30 subjects will complete all the study treatments. Omeprazole 20 mg will be administered before breakfast. Vecam 40/300 and Vecam 20/300 will be administered at bedtime w/o food. 24-hour gastric pH will be measured after the fifth dose (day 5).Following screening procedures, subjects will be randomly assigned to receive the different treatments.

All pH measurements will be done in the study center under supervised conditions. All drug administrations will be supervised.

This study is part of the Vecam clinical development plan.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Gastroesophageal Reflux
  • Drug: Omeprazole
    20 mg capsule, orally, once daily (before breakfast) for 5 days.
    Other Name: Omeprazole
  • Drug: Vecam
    1 capsule, orally, once daily at bedtime for 5 days.
    Other Name: vecam
  • Drug: Vecam
    1 capsule, orally, once daily at bedtime for 5 days.
    Other Name: Vecam
  • Active Comparator: Omeprazole 20 mg
    Intervention: Drug: Omeprazole
  • Experimental: Vecam 20/300
    Intervention: Drug: Vecam
  • Experimental: Vecam 40/300
    Intervention: Drug: Vecam
Chowers Y, Atarot T, Pratha VS, Fass R. The effect of once daily omeprazole and succinic acid (VECAM) vs once daily omeprazole on 24-h intragastric pH. Neurogastroenterol Motil. 2012 May;24(5):426-31, e208-9. doi: 10.1111/j.1365-2982.2012.01884.x. Epub 2012 Feb 28.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
June 2009
June 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy, H. pylori negative status (by Urea Breath Test)
  • Male or female subjects
  • Age 18-55 years
  • Able to tolerate the placement of a nasogastric pH probe at screening
  • Baseline Gastric pH≤2
  • Use of acceptable form of birth control in females with child-bearing potential
  • Had not used any form of tobacco (e.g. smoking or chewing) for the last year
  • Can swallow a size "00" capsule without difficulty
  • Willing to comply with study protocol
  • Signed Informed Consent form

Exclusion Criteria:

  • BMI > 40
  • Slow or poor Omeprazole metabolizers (heterozygous or homozygous, respectively) based on CYP2C19 genotyping test.
  • Any significant history of / or concurrent gastrointestinal diseases or conditions such as:

    • GERD
    • Acute gastrointestinal bleeding
    • Zollinger Ellison Syndrome or Gastric hypersecretory condition
    • Known Barrett's esophagus
    • Esophageal stricture
    • Peptic ulcer disease (gastric or duodenal) or family history of peptic ulcer disease
    • Gastric outlet obstruction
    • Gastroparesis
  • Significant medical history or concurrent illness as determined by the principal investigator
  • Any medical disorder that alters the normal gastric acid secretion profile as determined by the principal investigator
  • History of diabetes mellitus
  • Significant laboratory abnormalities as determined by the principal investigator
  • Known metabolic alkalosis, hypocalcemia, sodium restricted diet, hypokalemia, respiratory alkalosis
  • Pregnant or lactating women
  • Had been treated with any investigational drug or therapy or participated in a clinical trial within 30 days prior to entering the trial
  • Use of any medication other than contraception or hormone replacement therapy; OTC drugs other than vitamins or occasional acetaminophen within 30 days prior to entering the trial or during the trial
  • Use of NSAID medications within 30 days prior to entering the trial (e.g. Ibuprofen, Aspirin, Naproxen etc)
  • Positive urine test for alcohol or other drugs
  • Concurrent use of gastric anti-secretory drugs such as defined below:

    • Use of a PPI 30 days prior to each stage or during the trial
    • Use of H2RA 14 days prior to each stage or during the trial
    • Concurrent use of antacids (including over-the-counter) 24 hours prior to each stage or during the trial
  • Use of any medication that modifies gastric acid secretion 30 days prior to or during the trial.
  • Had ingested grapefruit within 14 days of dose administration in any trial period
  • Significant drug allergy or known hypersensitivity to any of the ingredients in the trial drugs Omeprazole, Succinic Acid or to Lidocaine
  • Consumption of coffee within 48 hours of dose administration in any trial period.
  • Had donated blood within 30 days of entering the trial
  • Known positive serology for HBV, HCV or HIV
  • Any reason which makes the subject a poor candidate based on the physician's discretion
Both
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00818870
VCT006
No
Richard E. Lowenthal, Vecta
Vecta Ltd.
Not Provided
Principal Investigator: Vijayalakshmi S Pratha, MD Clinical Applications Laboratories Inc.
Vecta Ltd.
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP